Vemurafenib Recruiting Phase 2 Trials for Malignant Melanoma Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02902029Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
NCT02303951Neoadjuvant Vemurafenib + Cobimetinib in Melanoma: NEO-VC